Age-Related Immune Response Heterogeneity to SARS-CoV-2 Vaccine BNT162b2

With new variants and waning immunity occurring, especially in elderly and immunocompromised individuals, it is important to understand how to utilize the tools we have to prevent severe disease and death.

New Advances in Cytotoxicity Assay Workflows using the Celigo Imaging Cytometer

The Celigo Image Cytometer has been previously used for a wide range of immuno-oncology and immunotherapy studies, demonstrating the great utility of this instrument to assess the activity of cytotoxic immune cells against malignant cells of interest.

Sangivamycin is highly effective against SARS-CoV-2 in vitro and has favorable drug properties

Sangivamycin is an unsuccessful anti-cancer drug candidate that has proven to be a potent inhibitor of multiple viruses. The authors of this study hypothesized that this compound would also be active against SARS-CoV-2.

Go to Top